CardioQ update

Deltex Medical Group PLC
15 April 2008

                            Deltex Medical Group plc

  UK NHS's Centre for Evidence-based Purchasing publishes evidence review and
             economic assessment of oesophageal Doppler monitoring

15 April 2008 - Deltex Medical Group plc ('Deltex Medical'), the UK's leading
haemodynamic monitoring company, today announces the results of a new report on
the CardioQ(TM) technology of oesophageal Doppler monitoring (ODM).

The report is an Evidence Review by the Centre for Evidence-based Purchasing
('CEP'), which is part of the Policy and Innovation Directorate of the NHS
Purchasing and Supply Agency. The report is 'based on evidence contained in a
high-quality 2007 systematic review of ODM in patients during surgery and
post-operatively from the US Agency for Healthcare Research and Quality (AHRQ)':
the Company notes that this is the same AHRQ review which drove the decision of
the Centers for Medicare and Medicaid Services to cover ODM for reimbursement
nationally across the USA.

In respect of use during surgery, the Company's key target market for the
CardioQ, the CEP report concludes:

'In patients undergoing high-risk surgery, addition of ODM-guided fluid
administration to CVP monitoring plus conventional clinical assessment
(comparison 1) is likely to result in fewer deaths, fewer complications, and a
shorter length of hospital stay. The costs of ODM are likely to be offset by
reductions in both complications and length of hospital stay (although the costs
of treatments prompted by monitoring are uncertain)'.

The economic analysis associated with this conclusion calculates a range of per
patient equipment costs of between £65.60 per patient and £214.15 per patient
(dependent on probe variant and frequency of use of the monitor). It also
calculated a range of savings per patient from using the CardioQ of between £642
and £4,441. Comparing the highest cost above with the lowest saving indicates
that the NHS saves at least £3.00 for every £1.00 it spends on the CardioQ: the
saving rises to £67.00 for every £1.00 spent on the CardioQ if the lowest cost
per patient is compared to the highest benefit.

CEP gives one of four verdicts to health technologies based on its evidence
reviews ranging from 'recommended' to 'not recommended'. In respect of ODM its
verdict is 'significant potential', although the Company notes that CEP has
never given any technology a higher verdict than 'significant potential'.

The CEP report provides an early synopsis of a technology assessment report
commissioned by the National Coordinating Centre for Health Technology
Assessment and which is due to be published in October 2008. The CEP report is
available at www.pasa.nhs.uk/PASAWeb/NHSprocurement/CEP.

Deltex Medical's Chief Executive, Andy Hill commented:

'The CEP report confirms once again the strong evidence that the CardioQ
significantly improves outcomes for large numbers of patients undergoing
surgery. This is the first UK Government commissioned economic analysis of the
potential impact of the CardioQ across the NHS and the results are stunning,
with savings identified of up £4,441 per patient. This report will make it
harder than ever before for the NHS to deny funding to those clinicians wishing
to use the CardioQ.

'We will be seeking to work closely with the report's authors over the coming
months to provide them with whatever extra information they feel they need in
order to recommend the CardioQ be formally recognised as a standard of care 
for a significant proportion of the 3,000,000 NHS patients who undergo surgery
every year.'

For further information, please contact:-

Deltex Medical Group plc                         01243 774 837
Nigel Keen, Chairman                             [e-mail]
Andy Hill, Chief Executive                       [e-mail]
Ewan Phillips, Finance Director                  [e-mail]

Gavin Anderson & Company                         0207 554 1400
Deborah Walter                                   [e-mail]
Robert Speed                                     [e-mail]
Stuart Macaulay                                  [e-mail]

Charles Stanley Securities                       020 7149 6000
(Nominated Adviser)
Philip Davies                                    [e-mail]
Russell Cook                                     [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM) monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already around 1,500 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange